Business Context and Reporting Period
This Form 8-K Current Report was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on July 3, 2008, regarding an event dated June 30, 2008. The filing discloses the entry into a Material Definitive Agreement between ChromaDex, Inc. (a wholly owned subsidiary) and The Research Foundation of State University of New York (SUNY Buffalo).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The only specific financial values disclosed relate to the terms of the new agreement:
- Annual Minimum Royalties: $5,000 payable to SUNY Buffalo.
- Up-front Payment: A cash payment for research funding is required within 30 days; the specific amount is not disclosed in this text.
- Milestone Payments: A payment is due upon the sale of the first licensed product or receipt of a sublicense fee; the specific amount is not disclosed.
- Patent Cost Reimbursement: ChromaDex must reimburse SUNY Buffalo for pre-existing patent costs over 11 months and future costs within 30 days of invoicing.
Material Changes
The primary material change is the execution of a Technology License Agreement on June 30, 2008. This agreement grants ChromaDex:
- A worldwide, exclusive license for nutraceutical, food additive, fine chemical, research, and cosmetic applications involving leucoanthocyanidins, anthocyanidins, and anthocyanins.
- A worldwide, non-exclusive license for pharmaceutical applications.
- An exclusive right to negotiate future licenses for technology improvements developed by specific SUNY Buffalo inventors.
Guidance, Outlook, and Risks
Commercialization Obligations: ChromaDex has agreed to use reasonable efforts to commercialize licensed products as soon as practicable. The company is subject to milestone events regarding development plan submissions, commercial availability dates, and annual sales revenue targets.
Risks and Contingencies:
- Indemnification: ChromaDex must indemnify SUNY Buffalo for third-party claims arising from the use of the licenses and maintain specific insurance levels.
- Sublicensing: Any sublicenses granted by ChromaDex require SUNY Buffalo's prior written consent, which cannot be unreasonably withheld.
- Confidentiality: Certain terms of the agreement are subject to confidential treatment and will be detailed in the subsequent Form 10-Q.
Investor Verification Checklist
- Verify the exact amount of the up-front cash payment for research funding, as it is not specified in this 8-K.
- Review the attached Technology License Agreement in the Form 10-Q for the quarter ended June 28, 2008, to see the full terms and confidential details.
- Confirm the specific milestone payment amounts and the annual sales revenue thresholds required to maintain the license.
- Assess the financial impact of the $5,000 annual minimum royalty and patent cost reimbursements on the company's cash flow.